The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level &lt;2.5ng/ml

Pashtan, Itai; Chen, Ming‐Hui; D’Amico, Anthony V.

doi:10.1016/j.canep.2014.07.007

Cited by 5 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usefulness of serum PSA measurement in prostate cancer diagnosis is well accepted [14]. However, according to the clinical observation there is a subgroup of men with low serum PSA, but actually with biologically aggressive PC and the relationship between PSA and clinical outcomes, including recurrence and death, in patients with serum PSA levels in normal range were explored in several studies [46][47][48]. Occurrence of PC progression despite very low PSA levels [49] indicates that new, more sensitive biomarkers to improve the diagnosis of BPH and PC, especially in patients with T2D are needed.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Serum Ghrelin Levels in Diabetic Men with Benign Prostate Hypertrophy

Wrzosek¹

2015

J Diabetes Metab

View full text Add to dashboard Cite

Introduction: The aim of this study was to assess relations between total ghrelin concentrations, PSA levels and other metabolic parameters in patients with Benign Prostate Hyperplasia (BPH) and in patients with BPH and coexisting Type 2 Diabetes (T2D) due to estimate its diagnostic value. Material and method: Altogether, 21 patients with BPH, 22 patients with BPH and coexisting T2D and 24 control subjects were enrolled in the study. All participants underwent a comprehensive medical evaluation including clinical history and urological examination. The following variables were determined for each subject: total ghrelin, total Prostate-Specific Antigen (PSA), fasting glucose, insulin, C-peptide, glycosylated hemoglobin (HbA1c), triglycerides, total cholesterol, high-density and low-density lipoprotein cholesterol, transaminases and creatinine. Results: Diabetic men with BPH had similar PSA levels as control men without BPH. In addition PSA concentrations were reduced in with coexisting T2D when compared with non-diabetic patients with BPH. There were no statistically significant differences in total ghrelin concentrations between diabetics with BPH as well as non-diabetics with BPH and controls, however, in non-diabetic patients with BPH there was significant positive correlation between serum PSA and total ghrelin concentrations (R=0.638; P=0.002). Discussion: We conclude that reduced concentration of PSA in subjects with coexisting T2D may delay the diagnosis and treatment of BPH in these patients. Further studies are needed to assess the diagnostic role of serum ghrelin levels in diabetic men with BPH.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Serum Ghrelin Levels in Diabetic Men with Benign Prostate Hypertrophy

Wrzosek¹

2015

J Diabetes Metab

View full text Add to dashboard Cite

show abstract

“…A decline in prostate cancer mortality has been observed since the Food and Drug Admini stration approved the use of the PSA test. Additionally, implementing PSA testing has allowed diagnosis of the disease at a much earlier and potentially more curable stage (Gulati et al, 2013;Kash, Lal, Hashmi, & Mubarak, 2014;Pashtan, Chen, & D'Amico, 2014). Some studies, however, have attributed the decline in prostate cancer mortality in the U.S. to improvements in cancer treatment (Etzioni & Feuer, 2008).…”

Section: Current Biomarkers For Clinical Prostate Cancer Testingmentioning

confidence: 99%